trial natriuretic factor (ANF) is an endogenous peptide hormone of cardiac origin that is stored in atrial granules as a 126-amino-acid pro-ANF molecule. [1] [2] [3] [4] [5] In response to atrial stretch, pro-ANF is cleaved by a membrane-bound protease and released into the circulation as a 28-amino-acid peptide.6,7 Studies support a biological role for ANF in the regulation of cardiorenal homeostasis in which physiological concentrations of ANF may increase sodium excretion, inhibit the renin-angiotensin-aldosterone system (RAAS), and decrease venous return. 8 Repeated studies have demonstrated that ANF synthesis and secretion by the heart are markedly enhanced in congestive heart failure, resulting in elevation of circulating concentrations.39-11 While elevated plasma ANF may serve to promote sodium excretion and antagonize the RAAS,12 severe symptomatic congestive heart failure is a clinical syndrome that demonstrates avid sodium retention and marked activation of the RAAS. Thus, severe symptomatic congestive heart failure is characterized by renal and endocrine hyporesponsiveness to endogenous ANF as well as to exogenous ANF.'314 While multiple mechanisms have been advanced to explain the biological resistance to endogenous ANF in congestive heart failure, such as receptor downregulation, the opposing actions of angiotensin II, and increased degradation of ANF,15-17 the release of an altered biologically active form of ANF has been proposed. '8,"9 Studies by Sugawara and coworkers20 have reported the presence of an antiparallel dimer form of ANF termed 13-ANF in atrial tissue of humans with severe congestive heart failure with minimal concentrations in patients with mild congestive heart failure. Recent The current study was therefore designed to determine the presence and relative concentration of f3-ANF in the plasma of patients with severe chronic congestive heart failure and normal volunteers. Second, the magnitude of elevation of this altered form of ANF was correlated with the degree of left ventricular dysfunction. Third, we investigated the role of human plasma and atrial tissue in the degradation of f3-ANF.
Methods
Patients and Normal Volunteers Eight normal subjects (mean age, 61±4 years; 6 men and 2 women) served as the control group. None had a history of cardiovascular, renal, liver, or metabolic disease, and none were taking medication. Twelve patients (mean age, 67±3 years; 10 men and 2 women) with congestive heart failure and New York Heart Association (NYHA) functional class IV were investigated. All congestive heart failure patients were on treatment, which included digitalis, diuretics, and/or vasodilators. None of the patients had intrinsic primary renal or hepatic dysfunction. The clinical profile and hemodynamic parameters of the NYHA class IV group are reported in Tables 1 and 2 . Hemodynamic Measurement
Arterial, right atrial, pulmonary wedge, left and right ventricular, and pulmonary arterial pressures were determined at the time of cardiac catheterization. Left ventricular ejection fraction was determined by left ventriculography performed at the time of cardiac catheterization. Normal left ventricular ejection fraction in the cardiac catheterization laboratory is more than 0.55. Cardiac output was determined by thermodilution. Cardiac index was determined by cardiac output divided by total body surface area.
Analysis
Blood for radioimmunoassay and cardiac hemodynamics was obtained at the time of cardiac catheterization. Venous plasma samples (3 mL) were obtained from antecubital space in normal subjects and chronic congestive heart failure patients and placed into iced EDTA tubes. Blood samples were centrifuged at 2500 rpm at 40C for 15 minutes, and the plasma then was removed and stored at -200C until analysis. Plasma levels of total ANF (a-plus 1B-ANF) were measured by an a-ANF radioimmunoassay as previously described.9
The radioimmunoassay had an equal molar cross-reactivity with a-and 8-ANF as determined by the addition of synthetic peptides to the assay. a-ANF and P-ANF were separated from nonextracted plasma by a P-6 (Bio-Rad Laboratories, Richmond, Calif) gel-filtration column (lx 13 cm).27 Five hundred microliters of nonextracted plasma was applied to the column and eluted with 0.5 M acetic acid buffer. Fractions of 0.5 mL were collected and dried by Speedvac. The concentration of ANF in each fraction was determined by radioimmunoassay.9 The P-6 column was calibrated with labeled aand pB-ANF (IQ`a -ANF and I`13-ANF) (Fig 1A) .
f3-ANF was eluted from fractions 5 through 9 (peak fraction at 7) and a-ANF from fractions 10 through 17 (peak fraction at 12). Total ANF recovery was determined by adding the concentrations of each fraction (5 through 17) after the substraction of background (5 pg per fraction). The amount of ANF measured in fractions 5 through 9 was calculated as 83-ANF and in fractions 10 through 17 as a-ANF. The percentages of a-and 83-ANF were determined from these calculated ratios. The mean column recovery of total ANF Results Table 3 gives the total ANF (a-plus 3-ANF) concentrations in the plasma of congestive heart failure patients and normal subjects. Total ANF was greater in the congestive heart failure group than in the normal group. Analysis by gel filtration of the molecular forms of ANF in the plasma demonstrated that ,B-ANF represented 61±2% of total plasma ANF in severe congestive heart failure, whereas a-ANF represented 39±3%. In marked contrast, no ,B-ANF was detectable in normal human plasma. Fig 1B is a representative gel filtration chromatogram from a normal subject. Total immunoreactive plasma ANF was 11.6 pg/mL. Gel filtration demonstrated peak activity at fraction 12 but none at fraction 7, indicating that f-ANF was not present in plasma from normal subjects. Fig 1C is a representative gel filtration chromatogram of a patient with severe congestive heart failure. Total ANF was 316 pg/mL, and gel filtration indicated the principal form to be 8-ANF (66% of total) with a smaller percentage (33%) migrating to the a-ANF calibration position. Fig 2A demonstrates contrast, peak area of fB-ANF was markedly decreased at 60 minutes in active tissue, and the peak area of a fragment smaller than a-ANF was increased. Table 4 reports the changes of peak area of f3-ANF in active tissue (n=5) and demonstrates that the peak area of f3-ANF was 39+2 mm2 at 0 minutes (baseline) and 27+1 mm2 after 60-minute incubation with 1125 f3-ANF. This is a decrease of 30±2% (P<.05) from the 0-minute value.
In contrast, J3-ANF was not converted in inactive tissue (35±3 mm2 at 0 minutes and 35±3 mm2 at 60 minutes) or in plasma (43 ±5 mm2 at 0 minutes and 44±6 mm2 at 60 minutes). Studies also revealed that a-ANF was 100% converted to a smaller fragment in active tissue but not in plasma.
Discussion The present study demonstrates that 83-ANF is present in high plasma concentrations and is the principal circulating form of ANF in patients with severe congestive heart failure. In marked contrast, 8-ANF is not present in plasma of normal humans. This study also reveals that the percent of 13-ANF increases as total ANF (a-and ,B-ANF) increases. Furthermore, the magnitude of plasma P-ANF elevation also increases with progressive ventricular dysfunction. Last, ,B-ANF appears to be degraded to a peptide fragment smaller than a-ANF in cardiac tissue but not in plasma.
Studies have demonstrated that plasma ANF is elevated in congestive heart failure9 and that this elevation is secondary to increased synthesis and secretion of ANF from the failing heart.'1128-30 Investigations also have reported that ANF elevation in congestive heart failure correlates positively with the functional class of congestive heart failure.'0 The current study importantly confirms the elevation of plasma ANF in severe congestive heart failure. The current investigation also extends previous reports to establish that the principal form of increased endogenous ANF in severe congestive heart failure is the antiparallel dimer p-ANF. This study therefore complements the elegant work of Sugawara and colleagues,20 which reported that the increase in total ANF tissue concentration in the atria of the human failing heart is mainly due to an increase in tissue ,B-ANF. While these previous studies did not determine if jB-ANF was increased in the circulation, the present study clearly establishes an important role for f3-ANF as a circulating hormone in humans with severe congestive heart failure.
The present study may have important functional implications in neurohumoral and renal regulation in congestive heart failure. Severe congestive heart failure is characterized by marked sodium retention and activation of the RAAS in association with marked arterial vasoconstriction. While previous studies in experimental acute congestive heart failure have suggested that increased endogenous ANF has important biological activity to preserve sodium excretion and partially inhibit the RAAS despite arterial hypotension,'2 a renal resistance to synthetic a-ANF is a hallmark of severe congestive heart failure.13"4'3' This resistance is mediated by multiple mechanisms, including receptor downregulation, the opposing actions of angiotensin II, and increased degradation of ANF.15-17 With regard to f3-ANF in vitro, reports have documented that p-ANF may have a reduced capacity to stimulate the production of cGMP, which is the second messenger for ANF.2' One could speculate that an additional potential mechanism for the renal, endocrine, and vascular adaptations in chronic congestive heart failure may be related to the release of an altered form of ANF that has reduced biological action.
The degradation of ,-ANF has not been investigated. In the processing of 83-ANF, it is speculated that ,3-ANF may be a postprocessing product of mature a-ANF in tissue of the failing heart. Such processing could be related to alterations in energy production, which favors dimerization as well as altered energy use or excitationcoupling mechanisms. The positive correlation between the magnitude of ,-ANF presence in plasma with the severity of ventricular dysfunction provides circumstantial support for this concept. An alternative mechanism could be that 18-ANF is the primary mature product of pro-hormone, as is a-ANF, and both are rapidly degraded. Although previous reports20 suggest that fB-ANF is derived from the heart, we cannot exclude that ,3-ANF is formed in the peripheral plasma of patients with congestive heart failure. The current study demonstrates that P-ANF may be degraded to a smaller-molecular-weight peptide and that this occurs only in active cardiac tissue and not in plasma.
In summary, the current study demonstrates that the principal form of circulating ANF in severe congestive heart failure in humans is ,-ANF. This altered form, which is reported to have reduced cGMP stimulating actions, increases in parallel with the magnitude of ventricular dysfunction, thus having implications in the role of ANF in the pathophysiology of congestive heart failure.
